On June 12, 2025, Editas Medicine, Inc. announced significant results from a study showing that their proprietary lipid nanoparticle technology achieved 58% editing levels in a region relevant for treating sickle cell disease and beta thalassemia, exceeding the necessary threshold for therapeutic effect. This update reinforces the efficacy of their delivery method in non-human primates and demonstrated minimal liver targeting compared to traditional methods.